REFERENCES:
1. Bassan R, Hoelzer D, Thomas X, et al. Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study. Adv Ther . 2019;36:870-879.
2. Gökbuget N, Dombret H, Giebel S, et al. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. Hematology (Luxembourg) . 2019;24:337-348.
3. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. InOtuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. The New England journal of medicine . 2016;375:740-753.
4. Topp MS, Gökbuget N, Zugmaier G, et al. Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia. J Clin Oncol . 2014;32:4134-4140.
5. Maude SL, Laetsch TW, Buechner J, et al, Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med . 2018;378:439-448.
6. Lanza F, Maffini E, Rondoni M, et al. CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for InOtuzumab Therapy in Adults. Cancers (Basel) . 2020;12:303.
7. Kantarjian H, Thomas D, O’Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer . 2004;101:2788-2801.
8. Thomas X. InOtuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia. Expert Opin Investig Drugs . 2012;21:871-878.
9. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. InOtuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 InO‐VATE study. Cancer . 2019;125:2474-2487.
10. Jabbour E, Gökbuget N, Advani A, et al. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with InOtuzumab ozogamicin in the phase III InO-VATE trial.Leuk Res . 2020;88:106283.
11. Papayannidis C, Sartor C, Dominietto A, et al. InOtuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.Hematol Oncol . 2021;39:580-583.
12. Gauthier J, Bezerra ED, Hirayama AV, et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood . 2021;137:323-335.
13. Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant . 2008;41:483-493.
24. Chan WYK, Lee PPW, Cheuk DKL, et al. Blinatumomab with donor lymphocyte infusions post-haploidentical hematopoietic stem cell transplantation as salvage therapy for relapsed refractory acute lymphoblastic leukemia post
chimeric antigen receptor T-cell therapy. Pediatr Blood Cancer. 2022:e29852.